NCT06106100尚未招募不适用
Efficacy and Safety of Endoscopic Anti-reflux Mucosal Ablation Therapy for Gastroesophageal Reflux Disease: a Single Blind Randomized Sham Controlled Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 68
- 主要终点
- Improvement of gastroesophageal reflux disease symptoms
研究概览
简要总结
The goal of this randomized clinical trial is to investigate the efficacy and safety of antireflux mucosal ablation (ARMA) for patients with refractory gastroesophageal reflux disease (GERD). The trial aim to evaluate :
- Efficacy of ARMA comparing with medical treatment alone (proton pump inhibitor (PPI)), using GERD-Health Related Quality of Life Questionnaire (GERD- HRQL questionnaire), improvement of acid exposure time and DeMeester score
- Safety and complications of ARMA Participants will be randomly divided into 2 groups. The intervention group will be undergone ARMA, and the control group will be undergone sham endoscopic treatment.
The primary endpoint will be symptoms relief (GERD-HRQL decreases > 50%). The secondary endpoint will be dosage adjustment of PPI, complications, improvement of acid exposure time and DeMeester score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged over 18 years old
- •History of GERD for over 6 months, who had received PPIs for over 6 months but still had symptoms of typical GERD symptoms (GERD-HRQL score of >8, acid reflux sensation or heartburn), and/or other symptoms as lump throat, night cough, acid related chest tightness (without other possible explanation of these symptoms)
- •Acid exposure time > 6%
- •DeMeester score ≥ 14.72
排除标准
- •Pregnancy
- •Hiatal hernia > 2cm or Flap Valve Hill grade III/IV
- •GERD LA grade C/D or esophageal ulcer
- •Abnormal anatomy of esophagus (esophagectomy, stricture, diverticulum)
- •Barrett's esophagus with dysplasia
- •Esophageal motility disorders
- •History of gastroparesis
- •Cirrhosis
- •Esophageal and gastric varices
- •Previous gastric surgery and anti-reflux procedures
- •History of scleroderma or dermatomyositis
- •Coagulation disorders (Bleeding tendency and coagulopathy)
- •History of oncological disease (not active within 2 years)
结局指标
主要结局
Improvement of gastroesophageal reflux disease symptoms
时间窗: 3 months
Clinical success is defined as more than 50% improvement of the GERD-HRQL questionnaire at 3 months after the ARMA procedure. The results are from minimal 0 points up to 50 points. The higher the points, the greater the symptoms.
次要结局
- Complication rate(12 months)
- PPI dependency(12 months)
- Changes in DeMeester score(12 months)
- Changes in acid exposure time(12 months)
- Changes in lower esophageal sphincter pressure(12 months)
研究者
相似试验
招募中
不适用
Antireflux Mucosectomy (ARMS) for Treatment of Gastroesophageal RefluxGastro Esophageal RefluxNCT04194723Chinese University of Hong Kong30
Unknown
不适用
ARMA for Postoperative GERD After Sleeve GastrectomyGastroesophageal RefluxNCT05259579Chinese University of Hong Kong15
已完成
不适用
ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)GERDNCT04243668Asian Institute of Gastroenterology, India216
招募中
不适用
Prophylactic EUS-guided Gastroenterostomy in Advanced Periampullary CancersCancer GiNCT05994521McGill University Health Centre/Research Institute of the McGill University Health Centre110
招募中
不适用
Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)Gastro Esophageal RefluxNCT05570448Midwest Veterans' Biomedical Research Foundation36